To compare the clinicopathologic features of ERBB2-low gastric cancer (GC) and ERBB2-null advanced GC, and to evaluate the independent association of ERBB2 status with survival outcomes.
Approach:
Data Collection: Demographic, clinical, and pathologic features were retrospectively collected, including treatment modalities and survival outcomes, from the time of diagnosis until the end of the study period.
Key Findings:
ERBB2-low cases exhibit clinicopathologic characteristics between ERBB2-positive and ERBB2-null subtypes.
The prognostic impact of ERBB2-low expression in advanced GC remains uncertain.
Absence of robust data on the genetic and immunologic landscape of ERBB2-low GC is noted.
Interpretation:
The study aims to clarify the biological and prognostic differences between ERBB2-low and ERBB2-null advanced gastric cancer.
Limitations:
The study is retrospective and may be subject to biases inherent in such designs.
No central pathology review was performed, which may affect the accuracy of ERBB2 status assessment.
Conclusion:
The findings may provide a rationale for the development of personalized therapeutic strategies for ERBB2-expressing gastric cancer.
